HBsAg

April 6, 2017April 6, 2017

ContraVir Reports New Mechanism of Action for Hepatitis B Virus Inhibitor CRV431

Hepatitis B, News

ContraVir Pharmaceuticals, a New Jersey-based biopharma company that develops and commercializes antiviral therapies, is providing new insights into the mechanism of action of its hepatitis B virus (HBV)-optimized cyclophilin inhibitor CRV431. ... Read more

January 19, 2017January 19, 2017

Quest Launches First US HBV Test to Assess Patients’ Response to Therapy

Hepatitis B, News

Quest Diagnostics launched a new quantitative test that will help doctors in the U.S. measure a patient’s response to therapy while being treated for hepatitis B virus (HBV) infection. Today, 2.2 ... Read more

March 4, 2015March 5, 2015

Serum Identified as a Key Factor in Chronic HBV Interferon Therapy Effectiveness

Hepatitis B, News

A recent study identified high levels of interleukin (IL)-23 in patients’ serum as a biomarker for chronic hepatitis B patients positive for hepatitis B e antigen (HBeAg) responding to pegylated ... Read more

February 4, 2015February 5, 2015

Tekmira Begins Phase I Clinical Trial Of TKM-HBV For Hepatitis B

News

Tekmira Pharmaceuticals Corporation, a leading company in the development of RNA interference (RNAi) therapeutics, recently announced they have successfully dosed the first subject in a Phase I clinical trial of TKM-HBV – a therapeutic drug ... Read more